Table 1.

Effect of RYGB on NAFLD.

Reference	Patients	Types of study	Main outcomes (improvement)	Follow-up (months)
Silverman et al. (30)	91	Retro	Steatosis and fibrosis	18.4
Mattar et al. (31)	70	Pros	Steatosis and fibrosis	15
Clark et al. (32)	16	Pros	Steatosis, inflammation, and fibrosis	0.8
Mottin et al. (33)	90	Retro	Steatosis (82%)	12
Klein et al. (34)	7	Pros	Fibrosis and inflammation	12
Barker et al. (28)	19	Pros	Steatosis, inflammation, and fibrosis	21.4
Csendes et al. (35)	16	Pros	Histology (80%)	22
de Almeida et al. (36)	16	Pros	Steatosis, inflammation, and fibrosis	23.5
Furuya et al. (37)	18	Pros	Steatosis and fibrosis	24
Liu et al. (38)	39	Retro	Steatosis, inflammation, and fibrosis	18
Weiner et al. (39)	116	Retro	Complete regression (83%)	18.6
Meretto et al. (40)	78	Retro	Resolved fibrosis (50%)	Unavailable
Vargas et al. (41)	26	Pros	Steatosis, inflammation, and fibrosis	16
Tai et al. (42)	21	Pros	Steatosis, inflammation, and fibrosis	12

Pros, prospective; Retro, retrospective.